218 related articles for article (PubMed ID: 22371319)
1. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Reardon DA; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Gururangan S; Peters KB; McLendon R; Sathornsumetee S; Rich JN; Lipp ES; Janney D; Friedman HS
Cancer; 2012 Oct; 118(19):4759-67. PubMed ID: 22371319
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Desjardins A; Quinn JA; Vredenburgh JJ; Sathornsumetee S; Friedman AH; Herndon JE; McLendon RE; Provenzale JM; Rich JN; Sampson JH; Gururangan S; Dowell JM; Salvado A; Friedman HS; Reardon DA
J Neurooncol; 2007 May; 83(1):53-60. PubMed ID: 17245623
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA; Egorin MJ; Quinn JA; Rich JN; Gururangan S; Vredenburgh JJ; Desjardins A; Sathornsumetee S; Provenzale JM; Herndon JE; Dowell JM; Badruddoja MA; McLendon RE; Lagattuta TF; Kicielinski KP; Dresemann G; Sampson JH; Friedman AH; Salvado AJ; Friedman HS
J Clin Oncol; 2005 Dec; 23(36):9359-68. PubMed ID: 16361636
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS
J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Reardon DA; Egorin MJ; Desjardins A; Vredenburgh JJ; Beumer JH; Lagattuta TF; Gururangan S; Herndon JE; Salvado AJ; Friedman HS
Cancer; 2009 May; 115(10):2188-98. PubMed ID: 19248046
[TBL] [Abstract][Full Text] [Related]
6. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
Reardon DA; Dresemann G; Taillibert S; Campone M; van den Bent M; Clement P; Blomquist E; Gordower L; Schultz H; Raizer J; Hau P; Easaw J; Gil M; Tonn J; Gijtenbeek A; Schlegel U; Bergstrom P; Green S; Weir A; Nikolova Z
Br J Cancer; 2009 Dec; 101(12):1995-2004. PubMed ID: 19904263
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Chinot OL; Honore S; Dufour H; Barrie M; Figarella-Branger D; Muracciole X; Braguer D; Martin PM; Grisoli F
J Clin Oncol; 2001 May; 19(9):2449-55. PubMed ID: 11331324
[TBL] [Abstract][Full Text] [Related]
9. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Dresemann G; Weller M; Rosenthal MA; Wedding U; Wagner W; Engel E; Heinrich B; Mayer-Steinacker R; Karup-Hansen A; Fluge O; Nowak A; Mehdorn M; Schleyer E; Krex D; Olver IN; Steinbach JP; Hosius C; Sieder C; Sorenson G; Parker R; Nikolova Z
J Neurooncol; 2010 Feb; 96(3):393-402. PubMed ID: 19688297
[TBL] [Abstract][Full Text] [Related]
10. CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Chamberlain MC; Glantz MJ
J Neurooncol; 2008 Sep; 89(2):231-8. PubMed ID: 18480965
[TBL] [Abstract][Full Text] [Related]
11. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
12. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Taal W; Segers-van Rijn JM; Kros JM; van Heuvel I; van der Rijt CC; Bromberg JE; Sillevis Smitt PA; van den Bent MJ
J Neurooncol; 2012 May; 108(1):195-200. PubMed ID: 22396071
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
14. Initial chemotherapy in gliomatosis cerebri.
Sanson M; Cartalat-Carel S; Taillibert S; Napolitano M; Djafari L; Cougnard J; Gervais H; Laigle F; Carpentier A; Mokhtari K; Taillandier L; Chinot O; Duffau H; Honnorat J; Hoang-Xuan K; Delattre JY;
Neurology; 2004 Jul; 63(2):270-5. PubMed ID: 15277619
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study.
Brandes AA; Basso U; Vastola F; Tosoni A; Pasetto LM; Jirillo A; Lonardi S; Paris MK; Koussis H; Monfardini S; Ermani M
Ann Oncol; 2003 Dec; 14(12):1727-31. PubMed ID: 14630676
[TBL] [Abstract][Full Text] [Related]
16. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A
J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788
[TBL] [Abstract][Full Text] [Related]
19. Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
Shah GD; Silver JS; Rosenfeld SS; Gavrilovic IT; Abrey LE; Lassman AB
J Neurooncol; 2007 Nov; 85(2):217-22. PubMed ID: 17594055
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
